Argos Therapeutics Secures $17,500,000 Series E Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=2e95e578-7d44-45d7-b77b-04220ba45a3c
Date
11/21/2013
Company Name
Argos Therapeutics
Mailing Address
4233 Technology Drive Durham, NC 27704 USA
Company Description
Argos Therapeutics (NASDAQ: ARGS) is developing breakthrough immunotherapies that target the unique features of a patient´s disease. This new generation of personalized cancer and infectious disease therapeutics, created using the Company´s “Arcelis” technology, trains the immune system to recognize and attack the disease.
Website
http://www.argostherapeutics.com
Transaction Type
Venture Equity
Transaction Amount
$17,500,000
Transaction Round
Series E
Proceeds Purposes
This funding further strengthens our ability to advance our ADAPT clinical trial. In addition, the company is now better positioned to consider and pursue a range of options to support our global manufacturing and commercialization plans based on the potential of our Arcelis technology platform.
M&A Terms
Venture Investor